RITA enhances chemosensivity of pre-B ALL cells to doxorubicin by inducing p53-dependent apoptosis

References

• Vogelstein B, Lane D, Levine AJ. Surfing the p53 network. Nature 2000;408:307–10.
   PubMed Web of Science ®Google Scholar
• Amundson SA, Myers TG, Fornace AJ. Roles for p53 in growth arrest and apoptosis: putting on the brakes after genotoxic stress. Oncogene 1998;17:3287–99.
   PubMed Web of Science ®Google Scholar
• Xu Y. Regulation of p53 responses by post-translational modifications. Cell Death Differ 2003;10:400–3.
   PubMed Web of Science ®Google Scholar
• Beroud C, Soussi T. The UMD-p53 database: new mutations and analysis tools. Hum Mutat 2003;21:176–81.
   PubMed Web of Science ®Google Scholar
• Soussi T, Wiman KG. Shaping genetic alterations in human cancer: the p53 mutation paradigm. Cancer Cell 2007;12:303–12.
   PubMed Web of Science ®Google Scholar
• Vazquez A, Bond EE, Levine AJ, Bond GL. The genetics of the p53 pathway, apoptosis and cancer therapy. Nat Rev Drug Discov 2008;7:979–87.
   PubMed Web of Science ®Google Scholar
• Brown CJ, Lain S, Verma CS, Fersht AR, Lane DP. Awakening guardian angels: drugging the p53 pathway. Nat Rev Cancer 2009;9:862–73.
   PubMed Web of Science ®Google Scholar
• Ventura A, Kirsch DG, McLaughlin ME, Tuveson DA, Grimm J, Lintault L, et al.. Restoration of p53 function leads to tumour regression in vivo. Nature 2007;445:661–5.
   PubMed Web of Science ®Google Scholar
• Xue W, Zender L, Miething C, Dickins RA, Hernando E, Krizhanovsky V, et al..: Senescence and tumour clearance is triggered by p53 restoration in murine liver carcinomas. Nature 2007;445:656–60.
   PubMed Web of Science ®Google Scholar
• Kastan MB. Wild-type p53: tumors can’t stand it. Cell 2007;128:837–40.
   PubMed Web of Science ®Google Scholar
• Marine JC, Lozano G. Mdm2-mediated ubiquitylation: p53 and beyond. Cell Death Differ 2010;17:93–102.
   PubMed Web of Science ®Google Scholar
• Chene P. Inhibition of the p53-hdm2 interaction with low molecular weight compounds. Cell Cycle 2004;3:460–1.
   PubMed Web of Science ®Google Scholar
• Klein C, Vassilev LT. Targeting the p53-MDM2 interaction to treat cancer. Br J Cancer 2004;91:1415–9.
   PubMed Web of Science ®Google Scholar
• Doggrell SA. RITA–a small-molecule anticancer drug that targets p53. Expert Opin Investig Drugs 2005;14:739–42.
   PubMed Web of Science ®Google Scholar
• Zhao CY, Szekely L, Bao W, Selivanova G. Rescue of p53 function by smallmolecule RITA in cervical carcinoma by blocking E6-mediated degradation. Cancer Res 2010;70:3372–81.
   PubMed Web of Science ®Google Scholar
• Issaeva N, Bozko P, Enge M, Protopopova M, Verhoef LG, Masucci M, et al.. Small molecule RITA binds to p53, blocks p53-HDM-2 interaction and activates p53 function in tumors. Nat Med 2004;10:1321–8.
   PubMed Web of Science ®Google Scholar
• Ito A, Kawaguchi Y, Lai CH, Kovacs JJ, Higashimoto Y, Appella E, et al.. MDM2-HDAC1-mediated deacetylation of p53 is required for its degradation. EMBO J 2002;21:6236–45.
   PubMed Web of Science ®Google Scholar
• Lu C, El-Deiry WS. Targeting p53 for enhanced radio- and chemo-sensitivity. Apoptosis 2009;14:597–606.
   PubMed Web of Science ®Google Scholar
• Zhao CY, Grinkevich VV, Nikulenkov F, Bao W, Selivanova G. Rescue of the apoptotic-inducing function of mutant p53 by small molecule RITA. Cell Cycle 2010;9:1847–55.
   PubMed Web of Science ®Google Scholar
• Strom E, Sathe S, Komarov PG, Chernova OB, Pavlovska I, Shyshynova I, et al.. Small-molecule inhibitor of p53 binding to mitochondria protects mice from gamma radiation. Nat Chem Biol 2006;2:474–9.
   PubMed Web of Science ®Google Scholar
• Chipuk JE, Green DR. Dissecting p53-dependent apoptosis. Cell Death Differ 2006;13:994–1002.
   PubMed Web of Science ®Google Scholar
• Selivanova G. Therapeutic targeting of p53 by small molecules. Semin Cancer Biol 2010;20:46–56.
   PubMed Web of Science ®Google Scholar
• Leach FS, Tokino T, Meltzer P, Burrell M, Oliner JD, Smith S, et al.. p53 Mutation and MDM2 amplification in human soft tissue sarcomas. Cancer Res 1993;53:2231–4.
   PubMed Web of Science ®Google Scholar
• Saha MN, Micallef J, Qiu L, Chang H. Pharmacological activation of the p53 pathway in haematological malignancies. J Clin Pathol 2010;63:204–9.
   PubMed Web of Science ®Google Scholar
• Fojo T. Commentary: novel therapies for cancer: why dirty might be better. Oncologist 2008;13:277–83.
   PubMed Web of Science ®Google Scholar
• Nahi H, Selivanova G, Lehmann S, Mollgard L, Bengtzen S, Concha H, et al.. Mutated and non-mutated TP53 as targets in the treatment of leukaemia. Br J Haematol 2008;141:445–53.
   PubMed Web of Science ®Google Scholar
• Dohner H, Fischer K, Bentz M, Hansen K, Benner A, Cabot G, et al.. p53 gene deletion predicts for poor survival and non-response to therapy with purine analogs in chronic B-cell leukemias. Blood 1995;85:1580–9.
   PubMed Web of Science ®Google Scholar
• Hawkins JM, Moorman AV, Hoffbrand AV, Martineau M, Wright FS, Mehta AB, et al.. Association of 17p loss with late-stage or refractory disease in hematologic malignancy. Cancer Genet Cytogenet 1994;77:134–43.
   PubMed Web of Science ®Google Scholar
• Mitani N, Niwa Y, Okamoto Y. Surveyor nuclease-based detection of p53 gene mutations in haematological malignancy. Ann Clin Biochem 2007;44:557–9.
   PubMed Web of Science ®Google Scholar
• Wilson WH, Teruya-Feldstein J, Fest T, Harris C, Steinberg SM, Jaffe ES, et al.. Relationship of p53, bcl-2, and tumor proliferation to clinical drug resistance in non-Hodgkin’s lymphomas. Blood 1997;89:601–9.
   PubMed Web of Science ®Google Scholar
• Gaidano G, Ballerini P, Gong JZ, Inghirami G, Neri A, Newcomb EW, et al.. p53 mutations in human lymphoid malignancies: association with Burkitt lymphoma and chronic lymphocytic leukemia. Proc Natl Acad Sci USA 1991;88:5413–7.
   PubMed Web of Science ®Google Scholar
• Lens D, De Schouwer PJ, Hamoudi RA, Abdul-Rauf M, Farahat N, Matutes E, et al.. p53 abnormalities in B-cell prolymphocytic leukemia. Blood 1997;89:2015–23.
   PubMed Web of Science ®Google Scholar
• Enge M, Bao W, Hedstrom E, Jackson SP, Moumen A, Selivanova G. MDM2-dependent downregulation of p21 and hnRNP K provides a switch between apoptosis and growth arrest induced by pharmacologically activated p53. Cancer Cell 2009;15:171–83.
   PubMed Web of Science ®Google Scholar